NICE are consulting on a new abbreviated technology appraisal (ATA) process….
"The aim of the ATA is to provide a less resource-intensive process for appraising technologies that provide similar or greater health benefits compared with those already recommended in NICE guidance for the same indication, at a similar or lower cost–for example, new drugs within an establishedtherapeutic class of treatments (such as a new TNF-alpha inhibitor or a new factor Xa-inhibiting oral anticoagulant). The process will help NICE to appraise new technologies efficiently, supporting patients and clinicians in accessing a broader range of treatment options. By adopting a practical and pragmatic approach, NICE can appraise technologies efficiently by avoiding unnecessary analysis and assessment."
Details are available here. The consultation closes on the 24th August.
